Research
Metabolic adaptation
After 6 months of semaglutide treatment, participants showed significant reductions in Psoriasis Area and Severity Index (PASI) by 48%, body mass index (BMI), and preperitoneal and superficial fat.
Semaglutide may be an effective treatment for improving psoriasis severity in obese patients.
GoodSupportsmedium confidence
After 6 months, participants showed significant reductions in PASI (-48%), body mass index (BMI), preperitoneal and superficial fat.
Why this rating
The study is a prospective cohort study.
Source
Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study
Joana Nicolau et al. · Clinical and Experimental Dermatology · 2025
cohort · n=43Cited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →